Topic:

M&A

Latest Headlines

Latest Headlines

Auxilium takes money, runs from inversion with $2.6B Endo deal

Endo found the magic number in its negotiations with Auxilium Pharmaceuticals, boosting its offer to $2.6 billion and finally convincing its target to abandon plans for a tax-saving deal.

Buzz: Unsated by its Durata deal, Actavis looks again to buy Allergan

Fresh off signing up to buy Durata Therapeutics for $675 million, Actavis is making another overture for the embattled Allergan, Reuters reports, potentially setting up a bidding war with the dogged Valeant Pharmaceuticals.

UPDATED: With Actavis poised to swoop in, Valeant eyes $4.5B hike in bid for Allergan

Valeant CEO J. Michael Pearson has said he's confident Allergan shareholders will vote in support of his company's hostile bid come December. But it never hurts to have a little insurance.

Med tech deal value up 363% in first half, with megadeals still pending

A recent report by Evaluate MedTech released at the annual AdvaMed med tech conference in Chicago found that M&A deal value in the med tech sector grew by 363% year over year in the first half of 2014 to $30 billion.

Allergan asks judge to nix Ackman's voting rights at special meeting

Allergan's still okay with holding a special shareholder meeting on Dec. 18, a date it last month agreed on with wannabe acquirer Valeant. It just doesn't want its pursuer's partner, Bill Ackman, to have a say.

Hyperion and Clal come to temporary terms over a $570M biotech boondoggle

Hyperion Therapeutics, which claims it was duped into a $570 million deal for an Israeli biotech, has reached a temporary agreement with the seller, calling off its lawyers for the moment while the two try to determine whether the drug at the heart of the acquisition has any future.

Is Teva knocking on Mylan's door? With inversion deal at risk, maybe

Teva and Mylan merge? Rumors are certainly swirling--and not for the first time, either. But while a potential deal might make financial sense, at least one analyst doesn't see it happening.

Actavis snaps up Durata, newly approved antibiotic in $675M buyout

Buyout-hungry Actavis--which is alternatively spotlighted as both a buyer and a possible buyout target--has snapped up Chicago-based Durata Therapeutics and its recently approved antibiotic Dalvance (dalbavancin) for $675 million plus a potential bonus.

Chiltern picks up an Asian CRO with eyes on oncology

CRO Chiltern has reached into Singapore for its latest acquisition, buying out an Asian clinical contractor to expand its geographic footprint and therapeutic reach.

Catalent bets on armed antibodies with Redwood buyout

In its first acquisition since going public over the summer, Catalent has bought up longtime partner Redwood Bioscience, bringing in proprietary technology for developing antibody-drug conjugates.